Eesti - eesti - Ravimiamet

pharmaswiss ceska republika s.r.o. - atsetüülsalitsüülhape - gastroresistentne tablett - 100mg 28tk; 100mg 10tk; 100mg 56tk; 100mg 500tk; 100mg 50tk; 100mg 20tk

Eesti - eesti - Ravimiamet

pharmaestica manufacturing oÜ - atsetüülsalitsüülhape - kihisev tablett - 324mg 10tk; 324mg 4tk

Eesti - eesti - Ravimiamet

pharmaestica manufacturing oÜ - atsetüülsalitsüülhape+askorbiinhape - kihisev tablett - 400mg+300mg 10tk; 400mg+300mg 20tk

Eesti - eesti - Ravimiamet

bayer uab - atsetüülsalitsüülhape - kaetud tablett - 500mg 80tk

Eesti - eesti - Ravimiamet

bayer uab - atsetüülsalitsüülhape+askorbiinhape - kihisev tablett - 400mg+240mg 10tk

Eesti - eesti - Ravimiamet

orion corporation - atsetüülsalitsüülhape - tablett - 500mg 50tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

bayer ag - rivaroksabaan - arthroplasty, replacement; venous thromboembolism - antitrombootilised ained - xarelto, co-manustada atsetüülsalitsüülhape (asa) üksi või koos asa pluss clopidogrel või ticlopidine, on näidustatud ennetamine atherothrombotic sündmuste täiskasvanud patsientidel pärast äge koronaarsündroom (acs) kõrgenenud südame biomarkerite. xarelto, co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events. täiskasvanud patsientidel, kellele tehti plaaniline puusa- või põlveliigese asendamise operatsiooni venoosse trombemboolia (vte) ennetamine. ravi süvaveenide tromboos (dvt) ja kopsuarteri emboolia (pe), ning ennetamine korduvate digi-tv ja pe täiskasvanutel. adultsprevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

Euroopa Liit - eesti - EMA (European Medicines Agency)

mylan ireland limited - rivaroksabaan - venous thromboembolism; pulmonary embolism; acute coronary syndrome; stroke; coronary artery disease; peripheral arterial disease; atrial fibrillation - antitrombootilised ained - rivaroxaban mylan co-administered with acetylsalicylic acid (asa) alone or with asa plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers.  rivaroxaban mylan co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events.  ------prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery.  treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults. -------adults prevention of stroke and systemic embolism in adult   patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

Eesti - eesti - Ravimiamet

kofeiin+atsetüülsalitsüülhape - suukaudne pulber - 10tk

Eesti - eesti - Ravimiamet

sanofi aventis - atsetüülsalitsüülhape - süstelahuse pulber ja lahusti - 500mg 20tk; 500mg 6tk